Billerica, Massachusetts-based Insulet Corporation, maker of the OmniPod Insulin pump, has just announced that it received the FDA clearance to commercialize its latest product the Omnipod Dash ...

Fully Closed-Loop System Feasibility Study to be presented at Insulet Symposium and in e-Poster during ATTD 2026 Real World Evidence of Settings Optimization in Omnipod 5 Users will also be shared ...

ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced ...

ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the ...

Insulet Corporation PODD is well-poised to gain in the coming quarters, backed by the strength of its revolutionary Omnipod 5 Automated Insulin Delivery (“AID”) system. The continued market expansion ...

The expanded approval for the Omnipod 5 system now allows automated insulin delivery (AID) for adults with type 2 diabetes, offering a new option for better glucose management without daily injections ...

Both moves have shown up in margin expansion. Insulet is currently enjoying adoption of its Omnipod Dash, which allows for access to personal blood glucose and insulin readings from the pump to a ...

Insulet has initiated a voluntary recall for certain lots of its Omnipod 5 pods following 18 serious adverse event (AE) reports associated with a defect in the automated insulin delivery (AID) system.

Insulet Corporation (NASDAQ: PODD), the leader in tubeless insulin pump technology with its OmniPod ® Insulin Management System (OmniPod System), today announced a license agreement and partnership ...